



US008884030B2

(12) **United States Patent**  
**Canales et al.**

(10) **Patent No.:** **US 8,884,030 B2**

(45) **Date of Patent:** **\*Nov. 11, 2014**

(54) **INHIBITORS OF FLAVIVIRIDAE VIRUSES**

(71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)

(72) Inventors: **Eda Canales**, San Mateo, CA (US); **Lee S. Chong**, Newark, CA (US); **Michael O'Neil Hanrahan Clarke**, Redwood City, CA (US); **Edward Doerffler**, Union City, CA (US); **Scott E. Lazerwith**, San Francisco, CA (US); **Willard Lew**, San Mateo, CA (US); **Michael Mertzman**, Belmont, CA (US); **Philip A. Morganelli**, Oakland, CA (US); **William J. Watkins**, Saratoga, CA (US)

(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/958,424**

(22) Filed: **Aug. 2, 2013**

(65) **Prior Publication Data**

US 2013/0323203 A1 Dec. 5, 2013

**Related U.S. Application Data**

(63) Continuation of application No. 13/006,761, filed on Jan. 14, 2011, now Pat. No. 8,524,764.

(60) Provisional application No. 61/295,576, filed on Jan. 15, 2010.

(51) **Int. Cl.**

**C07D 409/00** (2006.01)  
**A61K 31/497** (2006.01)  
**A61K 31/427** (2006.01)  
**C07D 493/04** (2006.01)  
**A61K 31/4545** (2006.01)  
**A61K 45/06** (2006.01)  
**C07D 409/14** (2006.01)  
**A61K 31/4535** (2006.01)  
**A61K 31/454** (2006.01)  
**A61K 31/4025** (2006.01)  
**C07D 413/12** (2006.01)  
**C07D 333/38** (2006.01)  
**A61K 31/501** (2006.01)  
**A61K 31/381** (2006.01)  
**C07D 409/12** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C07D 333/38** (2013.01); **A61K 31/497** (2013.01); **A61K 31/427** (2013.01); **C07D 493/04** (2013.01); **A61K 31/4545** (2013.01); **A61K 45/06** (2013.01); **C07D 409/14** (2013.01); **A61K 31/4535** (2013.01); **A61K 31/454** (2013.01); **A61K 31/4025** (2013.01);

**C07D 413/12** (2013.01); **A61K 31/501** (2013.01); **A61K 31/381** (2013.01); **C07D 409/12** (2013.01)

USPC ..... **549/59**; 549/60; 549/69

(58) **Field of Classification Search**

USPC ..... 549/69; 514/447  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,861,421 A 1/1999 Christensen, IV et al.  
6,881,741 B2 4/2005 Chan Chun Kong et al.  
6,887,877 B2 5/2005 Chan Chun Kong et al.  
7,402,608 B2 7/2008 Chan Chun Kong et al.  
7,521,473 B2 4/2009 Lee et al.  
7,569,600 B2 8/2009 Denis et al.  
8,501,714 B2\* 8/2013 Cho et al. .... 514/81  
8,524,764 B2\* 9/2013 Canales et al. .... 514/447  
8,569,302 B2\* 10/2013 Canales et al. .... 514/252.01  
2002/0002199 A1 1/2002 Jeppesen et al.  
2003/0229053 A1 12/2003 Chan Chun Kong et al.  
2004/0116509 A1 6/2004 Chan Chun Kong et al.  
2005/0119332 A1 6/2005 Jeppesen et al.  
2006/0142347 A1 6/2006 Chan Chun Kong et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

WO WO-02/100846 12/2002  
WO WO-02/100851 12/2002

(Continued)

**OTHER PUBLICATIONS**

U.S. Appl. No. 13/801,011, filed Mar. 13, 2013, Watkins et al.


(Continued)

*Primary Examiner* — James O. Wilson

*Assistant Examiner* — Alexander R Pagano

(57) **ABSTRACT**

Provided are compounds of Formula I:



Formula (I)

and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

**18 Claims, No Drawings**